Imatib 400mg Tablet

Imatib 400mg Tablet contains Imatinib mesylate, which is used in the treatment of several malignancies, including chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal stromal tumors, and dermatofibrosarcoma protuberans.

Uses of Imatib 400mg Tablet

• Chronic Myeloid Leukemia (CML)
• Acute Lymphoblastic Leukemia (ALL)
• Gastrointestinal Stromal Tumors (GISTs)
• Dermatofibrosarcoma Protuberans (DFSP)

How does the Imatib 400mg Tablet work?

Imatinib is a selective tyrosine kinase inhibitor (TKI) that targets the BCR-ABL fusion protein produced by the Philadelphia chromosome. It blocks this protein, preventing the signaling pathways that cause cancer cells to grow and spread, ultimately leading to apoptosis (cell death).

How to Use & Dosage

Take Imatib 400mg Tablet by mouth with water and food to reduce stomach irritation. In CML, the usual starting dose is 400 mg once daily. The dose may be increased up to 800 mg for GISTs based on response and tolerance. Your healthcare provider may adjust the dose according to your condition.

Take the medication with a full glass of water and food. Do not consume grapefruit or grapefruit juice while taking this medicine. Follow your doctor’s instructions carefully and continue taking the medicine exactly as prescribed. Do not stop treatment without consulting your healthcare provider. If you have difficulty swallowing the tablet, seek medical advice. If you suspect an overdose, contact emergency medical services immediately.

Possible Side Effects

• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Muscle cramps
• Rash
• Anemia
• Heart failure
• Edema
• Pleural effusion

Safety Advice

🩺 Kidney

Patients with kidney disease should use Imatib 400mg Tablet with caution. Dose adjustment may be required. Please consult your healthcare provider.

⚠️ Liver

Imatib 400mg Tablet should be used cautiously in patients with severe liver disease. Dose adjustment may be necessary. Please consult your healthcare professional.

🤰 Pregnancy

Imatib 400mg Tablet is not considered safe during pregnancy. It may cause harm to the unborn baby. Please consult your healthcare provider before use.

🤱 Breastfeeding

It is not known whether Imatib 400mg Tablet is safe during breastfeeding. The medicine may pass into breast milk and could harm a nursing infant. Please consult your healthcare provider.

🍺 Alcohol

It is not known whether it is safe to consume alcohol while taking Imatib 400mg Tablet. Please speak with your healthcare provider.

🚗 Driving

Imatib 400mg Tablet may cause side effects that can affect your ability to drive or operate machinery. Please consult your healthcare provider if you experience dizziness or other symptoms.

Storage Instructions

Store at room temperature (20°C to 25°C). Keep the tablets in a dry place away from moisture and direct sunlight. Store in the original packaging and keep out of the reach of children.

References

• FDA (Novartis). GLEEVEC (imatinib mesylate) Full Prescribing Information. 2016.
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Engl J Med. 2001;344(14):1031-1037.
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. N Engl J Med. 2002;347(7):472-480.
• Goodman & Gilman’s. The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill.
• Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.

Disclaimer

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.